Dopamine agonist medications, particularly cabergoline, are the standard first-line treatment for reducing elevated prolactin in men, normalizing levels in roughly 75 to 90 percent of cases depending on the size of the underlying cause. But the right approach depends entirely on why prolactin is high in the first place. A pituitary tumor, a medication side effect, and an underactive thyroid all push prolactin up through different mechanisms, and each calls for a different response. Understanding the cause is the real first step to bringing prolactin down.
Why Prolactin Goes Up in Men
Prolactin is kept in check primarily by dopamine, which acts as a brake on the pituitary cells that produce the hormone. Dopamine travels from the hypothalamus to the pituitary through a dedicated blood supply and binds to receptors on prolactin-producing cells called lactotrophs. When that signal is strong, prolactin stays low. When it’s disrupted, prolactin rises.
The most common pathological cause in men is a prolactinoma, a benign pituitary tumor made of lactotroph cells that churn out prolactin independent of normal dopamine control. Men tend to be diagnosed later than women, often presenting with larger tumors (macroprolactinomas) because the early symptoms are easy to dismiss. The most frequent complaints are decreased libido, erectile dysfunction, and sometimes breast tissue enlargement.
Medications are the other major culprit. Typical (older) antipsychotic drugs are the most frequent pharmaceutical cause of high prolactin, but the atypical antipsychotic risperidone is also a strong offender. Antidepressants with serotonergic activity, including SSRIs and MAO inhibitors, can raise prolactin too, though usually to a lesser degree. Other drug classes sometimes implicated include certain anti-nausea medications and opioids. The mechanism is almost always the same: these drugs either block dopamine receptors or reduce dopamine activity, lifting the brake on prolactin secretion.
Less commonly, primary hypothyroidism can drive prolactin up. When thyroid hormone is low, the hypothalamus increases production of thyrotropin-releasing hormone (TRH), which stimulates not just the thyroid axis but also prolactin release. Kidney disease is another non-pituitary contributor; prolactin is partially cleared by the kidneys, and in patients on dialysis, TSH and prolactin levels tend to track together, with higher prolactin correlated with lower residual kidney function. Fixing the underlying thyroid or kidney problem often brings prolactin back down without needing prolactin-specific treatment.
Getting the Diagnosis Right
A single elevated prolactin reading doesn’t automatically mean something serious. Stress, recent exercise, a large meal, and even the needle stick of a blood draw can bump prolactin temporarily. That’s why doctors typically confirm with a repeat fasting morning sample taken in a calm setting. Intense physical activity, especially high-intensity exercise above the anaerobic threshold, causes a sharp but temporary prolactin spike that can linger into recovery.
There’s a diagnostic trap worth knowing about. In men with very large pituitary tumors (roughly 3 cm or bigger), prolactin levels can come back falsely normal or only mildly elevated because of something called the hook effect, an artifact of the lab assay being overwhelmed by extremely high hormone concentrations. If a large pituitary mass is visible on imaging but prolactin seems only modestly raised, the lab should re-run the test after diluting the blood sample, typically at 1:100. The true prolactin level may turn out to be thousands of ng/mL higher than initially reported. Missing this can lead to the wrong diagnosis and the wrong surgery.
The degree of prolactin elevation often points toward the cause. Drug-induced hyperprolactinemia rarely pushes levels above 100 to 150 ng/mL. Microprolactinomas (tumors under 1 cm) usually produce levels in the low hundreds. Macroprolactinomas can send levels into the thousands. These ranges overlap enough that imaging is almost always needed to confirm or rule out a tumor, but the ballpark figure helps guide the workup.
How Elevated Prolactin Affects Male Hormones
High prolactin interferes with the hormonal cascade that produces testosterone. It suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, which in turn reduces the pituitary’s output of LH and FSH, the hormones that tell the testes to make testosterone and sperm. The result is a state of hypogonadism: low testosterone, reduced sex drive, erectile problems, fatigue, and sometimes infertility. In men treated with antipsychotics, this pathway is a recognized contributor to sexual side effects and hormonal disruption.
Some men with prolactinomas present with normal testosterone levels despite elevated prolactin, which can delay diagnosis. The hypogonadal symptoms may be subtle or attributed to aging, depression, or medication side effects, so prolactin isn’t checked. This is one reason prolactinomas in men tend to be caught at a larger size than in women, who typically notice menstrual irregularities earlier.
Cabergoline as First-Line Treatment
Cabergoline, a long-acting dopamine agonist taken once or twice a week, is the preferred medical treatment for prolactinomas in men of all sizes, including giant tumors. It works by mimicking dopamine’s action on lactotroph D2 receptors, suppressing prolactin release, gene expression, and even the growth of the tumor cells themselves.
The results are consistently strong. In a retrospective cohort of men with microprolactinomas, about 89 percent achieved normal prolactin levels within a median of four months, with prolactin dropping from a median of 70 ng/mL to 7 ng/mL and testosterone rising from around 2.7 ng/mL to 5.4 ng/mL. In a study following men with both macro- and microprolactinomas over 24 months of cabergoline therapy, prolactin normalized in roughly 76 percent of macroprolactinoma patients and 80 percent of microprolactinoma patients, and tumor diameter shrank by about 73 percent on average. Even in giant prolactinomas, where tumors were very large, cabergoline produced at least a 96 percent prolactin reduction in every patient studied, with normalization in half of them within the first three to six months.
Bromocriptine is the older alternative dopamine agonist. It still works, but head-to-head comparisons consistently favor cabergoline. In one direct comparison, cabergoline achieved a 93 percent prolactin reduction versus 87.5 percent for bromocriptine, with normalization in 82 percent versus 59 percent of patients. Side effects were also substantially less common with cabergoline: about 12 percent of patients experienced adverse events compared to 53 percent on bromocriptine. A large trial in women with hyperprolactinemic amenorrhea found a similar pattern, with cabergoline producing normal prolactin in 83 percent versus 59 percent for bromocriptine, and far fewer gastrointestinal complaints. Bromocriptine requires daily dosing and is more likely to cause nausea, dizziness, and nasal congestion, so most endocrinologists now reach for cabergoline first.
Safety Concerns with Dopamine Agonists
The main safety question around cabergoline involves the heart. In Parkinson’s disease patients, who take much higher doses (often 3 to 5 mg per day), ergot-derived dopamine agonists have been linked to heart valve fibrosis. This raised concern about whether lower prolactinoma doses (typically 0.5 to 2 mg per week) might carry the same risk.
The evidence at prolactinoma-level doses is reassuring but not entirely clean. A study comparing 70 patients on cabergoline for an average of about 55 months to 70 matched controls found no difference in moderate or severe valve regurgitation between the two groups. However, a meta-analysis pooling data from six studies found a modestly increased risk of tricuspid valve regurgitation in cabergoline-treated patients, with a prevalence ratio of about 1.4. No patients in that analysis had symptoms from the valve changes; it was purely an ultrasound finding. Current guidelines generally recommend periodic echocardiography for patients on long-term cabergoline, particularly at higher cumulative doses, though the threshold varies by institution.
A separate concern is impulse control disorders, including compulsive gambling, hypersexuality, and compulsive spending. These are well known in Parkinson’s patients on dopamine agonists and are increasingly recognized in prolactinoma patients too. The likelihood rises with higher cumulative doses and longer treatment duration. These behaviors can be subtle and embarrassing, so they often go unreported unless the doctor specifically asks.
When Surgery Makes Sense
Because dopamine agonists work so well, surgery is not the default treatment for prolactinomas. But it has a clear role in specific situations. The most common reason for surgery is failure of medical therapy, either because the drug doesn’t bring prolactin down enough or because side effects are intolerable. In one surgical case series, 70 percent of the patients who underwent surgery had failed dopamine agonist therapy, split roughly equally between intolerable side effects and insufficient response. The remaining 30 percent went straight to surgery, most because of pituitary apoplexy (sudden bleeding into the tumor) or acute visual loss from tumor pressing on the optic nerves. A small number simply preferred surgery over lifelong medication.
Transsphenoidal surgery, performed through the nose and sinuses to reach the pituitary, is the standard approach. In experienced hands, cure rates for microprolactinomas are high, though macroprolactinomas are harder to cure surgically. Even when surgery doesn’t fully normalize prolactin, it can debulk the tumor enough to make subsequent medical therapy more effective or lower the required medication dose.
Vitamin B6, Zinc, and Herbal Supplements
A few nutritional interventions have been studied, though the evidence is far more limited than for dopamine agonists.
High-dose vitamin B6 showed striking results in one trial of men with antipsychotic-induced hyperprolactinemia. Over 16 weeks, the B6 group saw a 68 percent reduction in prolactin, from about 95.5 to 30.4 μg/L, outperforming the comparison drug aripiprazole, which achieved only a 37 percent reduction. The proposed mechanism is that B6 is a cofactor in dopamine synthesis, so supplementing it may boost the brain’s own dopamine output. This is a single study in a specific population (treatment-resistant schizophrenia patients on antipsychotics), so it’s too early to generalize, but the results are interesting enough that it deserves further investigation.
Zinc has been studied mainly in men with kidney failure, who are prone to high prolactin because of impaired renal clearance. In zinc-treated dialysis patients, prolactin levels were significantly lower (about 11 ng/mL) than in untreated patients (about 29 ng/mL), and plasma zinc and serum prolactin showed a strong inverse correlation. Whether zinc supplementation helps men with normal kidney function and high prolactin is unknown.
Vitex agnus-castus (chasteberry) is an herbal preparation with a long folk-medicine history for hormonal complaints. A clinical study found that Vitex reduced prolactin in women with mild hyperprolactinemia to a degree comparable to bromocriptine, with prolactin dropping from about 946 mIU/L to 529 mIU/L. The catch is that this evidence is almost entirely from studies in women, the doses aren’t well standardized, and the magnitude of prolactin reduction is modest compared to pharmaceutical dopamine agonists. Men sometimes take it based on these results, but there’s no solid trial data to back that use.
Recovery of Testosterone and Fertility
One of the most important questions men have is how quickly testosterone and sexual function come back once prolactin is under control. The answer is that recovery is real but not always complete, and it takes longer than most people expect.
In a large cohort of men treated with dopamine agonists, testosterone rose from a mean of about 5.2 nmol/L to 9.6 nmol/L at six months and 13.1 nmol/L at 12 months, then plateaued. Recovery from hypogonadism occurred in 43 percent at six months, 50 percent at 12 months, and 54 percent at 24 months. The numbers were better in men whose prolactin fully normalized: 61 percent at six months, 69 percent at 12 months. A separate 24-month study found testosterone normalization in about 61 percent of men, with sperm volume and count recovering in all those who achieved normal testosterone, and motility recovering in over 80 percent. So while fertility potential improves substantially, a meaningful fraction of men don’t fully recover gonadal function and may need testosterone replacement or gonadotropin therapy on top of prolactin treatment.
What Happens When You Stop Treatment
Dopamine agonists control prolactinomas; they don’t always cure them. The question of when and whether to stop medication is one of the trickiest in the management of this condition.
Guidelines generally suggest considering withdrawal after at least two years of treatment if prolactin has been normal for a sustained period and the tumor has significantly shrunk. But recurrence rates are high. In one long-term follow-up study, the overall recurrence rate after stopping cabergoline was 54 percent, with an estimated 63 percent risk by 18 months. Most recurrences happened within the first year, with a median time of three months. The size of any remaining tumor remnant before withdrawal was the strongest predictor of relapse, with each additional millimeter of remnant increasing risk by about 18 percent.
A different study found somewhat lower recurrence rates: 24 percent in patients with nontumoral hyperprolactinemia, 31 percent with microprolactinomas, and 36 percent with macroprolactinomas, over two to five years of follow-up. In that cohort, no tumors regrew, but gonadal dysfunction returned in 22 percent of women and 39 percent of men who relapsed. The discrepancy in relapse rates between studies likely reflects differences in how long patients were treated, how much the tumor shrank, and how strictly “recurrence” was defined. The practical takeaway is that stopping medication is worth trying under the right circumstances, but close monitoring is essential, especially in the first year.
Drug-Induced Hyperprolactinemia Without a Tumor
If medication is the culprit, the simplest solution is switching to a drug that doesn’t raise prolactin, when that’s clinically possible. Among antipsychotics, risperidone and the older typical drugs are the worst offenders, while aripiprazole is actually a partial dopamine agonist and can lower prolactin rather than raise it. Some psychiatrists add low-dose aripiprazole specifically to counteract another antipsychotic’s prolactin-raising effect.
The challenge is that medication changes aren’t always safe or feasible, particularly in patients with schizophrenia whose psychotic symptoms are well-controlled on a prolactin-raising drug. In those cases, adding cabergoline or trying high-dose vitamin B6 as an adjunct are both options that have been studied, though the vitamin B6 data is limited to one trial. What matters is that the psychiatrist and endocrinologist communicate, because the stakes of destabilizing a psychiatric condition can outweigh the risks of moderate hyperprolactinemia.
Body Weight, Age, and Baseline Prolactin
Even without disease, prolactin levels in healthy people vary by sex, body weight, and to some extent age. In a study measuring 24-hour prolactin profiles in healthy adults, average prolactin was determined primarily by sex and body mass index, with higher BMI associated with higher basal prolactin secretion. Age didn’t significantly affect overall 24-hour prolactin concentrations, though men over 50 showed changes in the pattern of prolactin release, with more irregular, spikier secretion compared to younger men. These findings matter for interpretation: a mildly elevated prolactin in an overweight man doesn’t necessarily signal a tumor. Weight loss alone could bring levels down, though this hasn’t been studied in a controlled trial as a treatment for hyperprolactinemia specifically.
Exercise is another modifier. Physical activity, particularly intense exercise, triggers a sharp but temporary rise in prolactin that persists into the recovery period. This is a normal physiological response, not a pathological one. But it means that a prolactin level drawn right after a hard workout could be misleadingly high. Fasting, rested, morning blood draws remain the gold standard for accurate measurement.